

CORZYNA™

(ranolazine 500 mg extended-release tablets)

CORZYNA™ Patient d'Exception Bridging Program (no cost for 60 days)

KYE recognizes the importance of access to new and important therapies for your patients in Quebec. As a result, KYE is pleased to announce the CORZYNA™ Patient d'Exception Bridging Program in partnership with SRX Health (www.srxhealth.ca).

The program will provide a 60-day supply of CORZYNA™ 500 mg tablets at not cost to all patients who have had a patient d'exception application submitted for CORZYNA™ to RAMQ consistent with the INESSS criteria which are:

Indication reconnue pour le paiement

- ❖ pour le traitement d'appoint des personnes atteintes d'angine stable depuis au moins trois mois:
 - qui présentent des symptômes d'angine à l'effort; et
 - qui restent symptomatiques malgré l'utilisation d'un bêta-bloquant, d'un bloquant des canaux calciques et d'un nitrate à longue durée action, à moins de contre-indication, d'intolérance sérieuse ou d'inefficacité.

You will simply need to complete the enrollment form and obtain patient consent; as well as provide a prescription for CORZYNA™ to the patient to use after the 60 days at no cost has ended.

The enrollment form is available as a PDF at www.kyepharma.com or by contacting your local KYE Medical Representative.

Click here for a digital copy of the [CORZYNA Patient d'Exception Bridging Program Enrollment Form](#)

Enrollment and Access Steps:

1. Complete electronic patient d'exception application consistent with the INESSS criteria via RAMQ website
2. Patients and their healthcare provider must complete the CORZYNA™ Patient d'Exception Bridging Program enrollment form.
3. Fax the CORZYNA™ Patient d'Exception Bridging Program enrollment form to: (1-855-CORZYNA / 1-855-267-9962)
4. The bridging program manager (SRX Health) will contact the patient and coordinate medication shipment or pharmacy pickup with the enrolled patient.

For more information, please contact CORZYNA@kyepharma.com.